Efficacy And Safety Of Talquetamab, A Gprc5d×cd3 Bispecific Antibody, In Chinese Patients With Relapsed/refractory Multiple Myeloma From The Phase 1/2

Talquetamab (tal) is the first bispecific antibody targeting the novel antigen, GPRC5D, approved in the US andEU for treatment of patients (pts) with relapsed/refractory multiple myeloma (RRMM). Approval was based ondata from the MonumenTAL-1 study demonstrating high overall response rates (ORRs; >71% at the recommended phase 2 doses [RP2Ds] of tal) in pts with RRMM. Pts from China were not included in the initialMonumenTAL-1 study results.